title: [Current perspectives on the repackaging and stability of solid oral doses].
abstract: Which are the guidelines and scientific aspects for repackaged oral solid medications in France in 2010 whereas it develops? The transient or definitive displacement of the solid oral form from the original atmosphere to enter a repackaging process, sometimes automated, is likely to play a primary role in the controversy. However, the solid oral dose is to be repackaged in materials with defined quality. Considering these data, a review of the literature for determination of conditions for repackaged drug stability according to different international guidelines is presented in this paper. Attention is also paid to the defined conditions ensuring the conservation and handling of theses drugs throughout the repackaging process. However, there is lack of scientific published stability data. Nevertheless, recent alternatives may be proposed to overcome the complexity of studying stability in such conditions. Then, the comparison of the moisture barrier properties of the respective package, a galenic model of hygroscopic molecules, or light sensitive molecules or stability data obtained during the industrial preformulation phase could also secure the list of drugs to be reconditioned. Similarly, a wise precaution will be to get stability data for the industrial blisters and unit doses undergoing the real conditions of the medication use process in hospitals and other healthcare settings. By now, reduction of dispensing errors and improvement of the compliance aid put a different perspective on the problem of repackaged drugs. To date, the pharmacist is advised to carry out its analysis of the risks.
authors.affiliation: Service pharmacie laboratoire, centre hospitalier spécialisé, Mas et IME de la Charité, 51 rue des Hostelleries, La Charité-sur-Loire, France. fabrice.lagrange@chs-lacharite.fr
authors.forename: F
authors.initials: F
authors.lastname: Lagrange
mesh_terms: D002626:Chemistry, Pharmaceutical; D002980:Climate; D004304:Dosage Forms; D004340:Drug Contamination; D004344:Drug Incompatibility; D004345:Drug Industry / Q000639:trends; D004348:Drug Labeling; D004349:Drug Packaging / Q000639:trends*; D004355:Drug Stability; D005602:France; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D004304:Dosage Forms